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Protein kinase B (PKB/Akt) belongs to the AGC superfamily of related serine/threonine protein kinases. It is a key
regulator downstream of various growth factors and hormones and is involved in malignant transformation and
chemo-resistance. Full-length PKB protein has not been crystallised, thus studying the molecular mechanisms that are
involved in its regulation in relation to its structure have not been simple. Recently, the dynamics between the inactive
and active conformer at the molecular level have been described. The maintenance of PKB’s inactive state via the
interaction of the PH and kinase domains prevents its activation loop to be phosphorylated by its upstream activator,
phosphoinositide-dependent protein kinase-1 (PDK1). By using a multidisciplinary approach including molecular
modelling, classical biochemical assays, and Fo ¨rster resonance energy transfer (FRET)/two-photon fluorescence lifetime
imaging microscopy (FLIM), a detailed model depicting the interaction between the different domains of PKB in its
inactive conformation was demonstrated. These findings in turn clarified the molecular mechanism of PKB inhibition
by AKT inhibitor VIII (a specific allosteric inhibitor) and illustrated at the molecular level its selectivity towards different
PKB isoforms. Furthermore, these findings allude to the possible function of the C-terminus in sustaining the inactive
conformer of PKB. This study presents essential insights into the quaternary structure of PKB in its inactive
conformation. An understanding of PKB structure in relation to its function is critical for elucidating its mode of
activation and discovering how to modulate its activity. The molecular mechanism of inhibition of PKB activation by
the specific drug AKT inhibitor VIII has critical implications for determining the mechanism of inhibition of other
allosteric inhibitors and for opening up opportunities for the design of new generations of modulator drugs.
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Introduction
Protein kinase B (PKB/Akt) is a key regulator downstream
of various growth factors and hormonal signals. It activates a
panel of proteins that regulate proliferation, growth, survival,
or metabolism and is involved in human cancer [1,2]. In
particular, its overexpression induces malignant transforma-
tion and chemoresistance [3]. PKB belongs to the AGC
superfamily of related serine/threonine protein kinases.
Three isoforms of PKB exist in mammals (PKBa/Akt1,
PKBb/Akt2, and PKBc/Akt3) that comprise an N-terminal
pleckstrin homology (PH) domain, a ﬂexible hinge between
the PH and the kinase domain, a catalytic (kinase) domain,
and a C-terminal regulatory part (containing a hydrophobic
motif, or HM) (for review [4,5]). The phosphorylation of Thr
308 in the kinase domain of PKBa/Akt 1 by phosphoinositide-
dependent protein kinase-1 (PDK1) [6] and Ser 473 in the
hydrophobic motif by mTORC2 complex [7] and/or DNAPK
[8], is central for PKB activation [9]. These phosphorylations
were shown to be dependent on the colocalisation of PKB
and PDK1 at the plasma membrane through the interaction
of their PH domains with PtdIns (3,4,5) P3 and PtdIns (3,4) P2
for the former [10–12] and PtdIns (3,4,5) P3 for the latter [13].
The dephosphorylation of these residues by okadaic acid-
sensitive and -insensitive phosphatases was shown to deacti-
vate PKB [14,15].
Recently, the cytoplasmic interaction of inactive PKB with
PDK1 was published [14]. The maintenance of PKB in an
inactive conformation by the interaction of its PH and kinase
domains (PH-in) prior to stimulation prevented the phos-
phorylation of Thr 308 by the associated PDK1. Upon
stimulation, PKB PH-domain interaction with phosphoinosi-
tides and its concomitant change in conformation allowed
the separation of the PH and kinase domains and the
associated co-recruited PDK1 to phosphorylate Thr 308.
Here, the intramolecular interactions of the PKB domains
in its inactive conformation were studied in detail using
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PLoS BIOLOGYmolecular dynamics in conjunction with classical biochemical
approaches and in situ Fo ¨rster resonance energy transfer
(FRET)/two-photon ﬂuorescence lifetime imaging microscopy
(FLIM). A PH domain-induced cavity was discovered in the
inactive PKBa kinase domain. The formation of this structure
was dependent on the PH domain residue Trp 80. The
position of PKBa C-terminal HM at the apex of the PH
domain-induced cavity in the inactive conformation of PKB
was also described. Unlike in PKBa, a PH domain-induced
cavity did not appear in PKBc suggesting a potential role of
this structure in a differential regulation of these two PKB
isoforms.
These ﬁndings led to the elucidation of the molecular
mechanism of inhibition of PKB by the highly speciﬁc
allosteric inhibitor, AKT inhibitor VIII, and its relationship
to the C-terminal HM motif of PKB.
Results and Discussion
Previously, the molecular model of the inactive PKB
conformer (PH-in conformer) showed that the PH and kinase
domains interacted [14]. By using molecular dynamics, an
unpredicted formation of a PH-induced cavity in the PKB
kinase domain was observed (Figure 1A). The location of this
cavity appeared to be in the same region as the PKB
hydrophobic pocket (binding site for PKB HM) described in
the crystal structure of the isolated PKB kinase domain [16].
The initial docking model of the PKB PH and kinase domains
interaction prior to performing molecular dynamics revealed
that the residue Trp 80, critically positioned at the tip of the
VL3 loop of the PH domain, was buried deep inside the PKB
kinase domain cleft in the PH-in conformer. However, the
reﬁned dynamic model showed that through this PH-induced
cavity, the Trp 80 residue, located at its centre, was accessible
from outside, whereas PKB remained in its inactive con-
former (Figure 1A-b).
To illustrate the importance of the positioning of the Trp
80 and the PH-induced cavity, we took advantage of a speciﬁc
PKB inhibitor, AKT inhibitor VIII [17–19] (Figure 1B,
chemical structure). The selectivity has been attributed to
an allosteric mode of binding, noncompetitive with ATP or
substrates, and with a mechanism of action dependent on the
presence of the PH domain of the full-length protein. In vivo
AKT inhibitor VIII prevented the phosphorylation of Thr 308
and Ser 473 (Figure 1B, western blot, and [20]), and as a result,
it was proposed to target a speciﬁc PKB conformation.
Recently, its efﬁcacy was shown to be dependent on the
presence of the Trp 80, but the molecular mechanism was not
determined [21]. The targeting of the PKB inactive conformer
by AKT inhibitor VIII and consequent prevention of PKB
conformation change was a plausible explanation for the loss
of Thr 308 phosphorylation.
To verify this postulate in vivo, experiments with the PKB
ﬂuorescent probe (green ﬂuorescent protein [GFP]-PKB-
monomeric red ﬂuorescent protein [mRFP]) [14] were
performed. The platelet-derived growth factor (PDGF)-
induced change in the conformation of PKB was monitored
by FRET/two-photon FLIM (Figure 1C). The pretreatment of
NIH3T3 cells with AKT inhibitor VIII prevented both the
translocation of GFP-PKB-mRFP to the plasma membrane
and its change in conformation induced by PDGF. To
illustrate the importance of the interaction of the inhibitor
with Trp 80, the GFP-PKB W80A-mRFP mutant was used.
Upon PDGF stimulation, the W80A mutant behaved as wild-
type PKB. However, in response to PDGF, it was evident that
the mutant was not inhibitor sensitive. The graphs in Figure
1C illustrate the statistical data obtained by FRET/two-photon
FLIM. These results established that the inhibitor ‘‘locked’’
PKB in its PH-in conformer and conﬁrmed in vivo the
importance of the Trp 80 residue in this mechanism.
The inhibition of PDGF-induced Thr 308 and Ser 473
phosphorylation by preincubation with increasing doses of
AKT inhibitor VIII was tested on GFP-PKBa and on the Trp
80 mutant (Figure 1D). At 5 lM AKT inhibitor VIII, the
phosphorylation of Thr 308 was inhibited by 95%, but Ser
473 was inhibited by only 70%. This differential in the
inhibition of Thr 308 phosphorylation compared to Ser 473
indicated that the mechanism of action of the inhibitor
affected the two sites in a distinct manner. The mutation of
the Trp 80 to Ala prevented entirely the loss of Thr 308
phosphorylation induced by 5 lM inhibitor, conﬁrming that
the loss of this critical residue prevented the locking of PKB
in the PH-in conformation as observed in Figure 1C.
However, the possibility that the inhibitor might still
interfere with the second site phosphorylation could not be
excluded since a slight decrease of Ser 473 phosphorylation
was observed in the W80A mutant.
To understand the signiﬁcance of the Trp 80 residue in
PKB, the interaction of PKBa PH mutant W80A with the
kinase domain in the PH-in conformation was determined by
molecular dynamics (Figure 2-c and 2-d). The alteration of
the shape and length of the PH domain-induced cavity in the
mutant PKBa W80A as compared to wild-type PKBa is
illustrated in Figure 2-c and 2-d (compare to Figures 1A-b,
and 2-a). Both cavities are ﬁlled with water molecules
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Author Summary
A critical protein in cell-signalling pathways, called protein kinase B,
regulates many aspects of cell biology from metabolism to
proliferation and survival, by modifying other proteins with the
addition of a phosphate group. Hence, deregulation of its activity
has acute consequences on cell function. Increased activity of a
tumour-promoting form of protein kinase B or of upstream
regulatory proteins has been observed in tumours, while impaired
protein kinase B function has been linked to diabetes. Therefore,
understanding the molecular mechanism of protein kinase B
activation will help reveal how its activity might be regulated to
limit disease progression. Toward this end, we studied how protein
kinase B structure relates to its function, to identify molecular
mechanisms regulating its kinase activity, modifying its cellular
localization, and altering its binding to other proteins. By determin-
ing the spatial organization of different regions of the protein in
inactive protein kinase B, we discovered a cavity at the interface of
two distinct functional regions of the inactive form. We also
localized the C-terminal end of the protein to the apex of the cavity,
suggesting a role of this domain in regulating the inactive form of
the protein. This represents a novel example of negative regulation
by inhibition across these different regions of the protein. From
these findings, we elucidated the mechanism of action of a highly
specific protein kinase B inhibitor, AKT inhibitor VIII. We determined
that simultaneous binding of the inhibitor to the two different
functional regions, through the cavity, ‘‘locks’’ protein kinase B in an
inactive conformation and prevents regulatory proteins from
accessing the C-terminal domain.represented in khaki or grey pearls (Figure 2-a and 2-d). More
remarkably, the distance between residue 80 and the protein
surface (red arrows) was increased in PKBa W80A (14 A ˚ )
compared to wild type (8 A ˚ ). Furthermore, the maximum
width of the cavity was reduced in the W80A (6–7 A ˚ )
compared to the wild type (8–9 A ˚ ). Figure 2-b presents the
model of interaction of AKT inhibitor VIII with the PH-
induced cavity of PKBa. Since the model showed a structure
of the inhibitor strongly compatible with the length and the
shape of the cavity in PKBa, a molecular simulation of the
Figure 1. In PKBa Inactive Conformation the PH Domain Creates a PH Domain-Induced Cavity in the Kinase Domain, Binding Site for AKT Inhibitor VIII
(A) The structure of the PKBa PH domain (pink) and reconstructed kinase domain (green) is shown in panel (a) in complex (PKBa PH-in conformer) after
short dynamic runs and minimisation in water and physiological salt concentration. The secondary structure of the kinase domain is represented as a
white ribbon. The PH domain residue Trp 80 located deep inside the kinase domain cleft is shown in red. The image in panel (b) was obtained by
rotation of 908 about the x-axis of the image panel (a). From this view, Trp 80 (red) is visible through an open cavity in the kinase domain.
(B) NIH3T3 cells were transfected with GFP-PKBa-RFP wt or Trp 80 Ala mutant constructs. The next day, the cells were treated with 50 lM of AKT
inhibitor VIII for 30 min prior to 5-min PDGF stimulation as indicated. The expression of the fusion proteins and their phosphorylation on Thr 308 were
determined by western blotting with an anti-PKB antibody (pan Akt) and a phosphospecific antibody, respectively. Thr 308 phosphorylation of
endogenous PKB is shown in the lower panel. The chemical structure of AKT inhibitor VIII is represented above the western blot.
(C) Two-photon FLIM images of NIH3T3 cells transfected either with GFP-PKBa or GFP-PKBa-mRFP wt or Trp 80 Ala mutant as indicated. The top panels
present intensity images of the donor GFP chromophore in the transfected cells after two-photon excitation. The central panels present intensity
images of the acceptor chromophore mRFP obtained with a mercury (Hg) lamp. The bottom panels present the calculated lifetime maps of the donor
GFP-PKBa or GFP-PKBa-mRFP. The lifetimes are presented in a pseudo-colour scale going from 2.0 ns (red) to 2.7 ns (blue). The cells were treated with
50 lM of AKT inhibitor VIII for 30 min prior to 5-min PDGF stimulation as indicated. The statistical distributions of lifetimes in each condition are shown
as box and whiskers plots: GFP-PKBa-mRFP (left graph) and Trp 80 Ala (right graph). The statistical analysis was performed on at least 15 cells in three
independent experiments. The p-values between two conditions are indicated on the graphs.
(D) The graphs present the effect of a dose response of AKT inhibitor VIII on Thr 308 (upper graph) and Ser 473 (lower graph) phosphorylations of GFP-
PKBa wt and Trp 80 Ala mutant. The values plotted have been normalised to 5-min PDGF stimulation for each constructs. The quantifications were
performed using the Odyssey/LI-COR fluorescence detection system.
doi:10.1371/journal.pbio.1000017.g001
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Regulation of PKB Inactive Conformerinteraction of the inhibitor with the PKBa PH-in structure
(Figure S1) was performed. Following a 1-ns dynamic run,
AKT inhibitor VIII was deeply and stably embedded in the
cavity of wild type PKBa. A distance of 4 A ˚ measured from the
quinoxalin head of AKT inhibitor VIII to Trp 80 suggested a
possible interaction by hydrogen bonding. Therefore, the
docking of AKT inhibitor VIII in the PH-induced cavity and
its interaction with Trp 80 would maintain PKB in the
inactive conformer. Conversely, the deformation of the cavity
in the Trp 80 Ala mutant (Figure 2-e) and the loss of bonding
with the 80 Ala residue, located farther away in the structure,
would explain the loss of inhibitor effect.
To understand whether this dynamic model was compat-
ible with the reported selective effect of AKT inhibitor VIII
towards PKBa and -b compared to PKBc [17,20], the
reconstruction of a full-length PKBc based on the PKBa
model described above, was made and a dynamic run of PKBc
in the PH-in conformation was performed (Figure 3A).
Contrary to PKBa, a PH domain-induced cavity was not
formed in PKBc (Figure 3A-a and 3A-b). However, the
dynamic structure revealed that Trp 79 (equivalent to Trp
80 in PKBa) was accessible, since it was positioned close to the
surface (6 A ˚ ). A dose response of inhibitor VIII indicated a
lower sensitivity for PKBc compared to PKBa. An inhibition
of Thr 308 and Ser 473 phosphorylations of only 50% and
30%, respectively, was observed at 5 lM inhibitor (Figure 3A).
The mechanism of inhibition also required the presence of
the residue Trp 79, as AKT inhibitor VIII failed to inhibit the
phosphorylation of Thr 308 and Ser 473 in the mutant GFP-
PKBc W79A. These data indicated that the mechanism of
inhibition of PKBc was speciﬁc and similar to PKBa, although
less potent. Since the major difference between the two
isoforms was the presence of the PH domain-induced cavity, a
possible explanation for a reduced sensitivity of PKBc was
that the absence of the cavity impaired the access of the
inhibitor to Trp 79.
To further probe this behaviour, a chimera was engineered
between the PH domain and linker of PKBa, and the kinase
domain and C-terminal part of PKBc (Figure 3B). Two
dynamic runs (8 ns and 10 ns) of the chimera PHa-KINc in
the PH-in conformation were performed (Figure 3B). The
partial reopening of an unstable PH domain-induced cavity
Figure 2. Model of AKT Inhibitor VIII Positioned in the PH Domain-Induced Cavity
The image in panel (a) is a vertical cross section of the dynamic structure shown in Figure 1A at the level of the PH-induced cavity. The distance
between the Trp 80 residue in red and the protein surface is about 8–8.5 A ˚ (red arrow). The cavity is filled with water molecules shown as khaki pearls. In
panel (c), the dynamic structure of the PH domain mutant Trp 80 Ala (purple) interacting with the wild-type kinase domain (yellow) is shown from the
same angle as in Figure 1A-b. The Ala 80 in light blue is positioned differently compared to Trp 80. On the vertical cross section (d), the PH-induced
cavity is not properly formed. Fewer water molecules accommodate the cavity (grey pearls), and the distance between Ala 80 and the surrounding
water environment has increased (14–15 A ˚) compared to Trp 80 (red arrows). The modelled positions of AKT inhibitor VIII (blue chemical structure) in
the PH-induced cavity of PKBa and PKBa Trp 80 Ala mutant are shown in panels (b) and (e), respectively.
doi:10.1371/journal.pbio.1000017.g002
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Regulation of PKB Inactive Conformerwas observed in the chimera PHa-KINc (Figure 3B-a through
3B-d). Concomitantly, the sensitivity of the chimera PHa-
KINc for AKT inhibitor VIII was enhanced compared to
PKBc (Figure 3B, right graphs). An inhibition of Thr 308 and
Ser 473 phosphorylation of 80% and 55%, respectively, at 5
lM was observed. However, the increased sensitivity of the
chimera PHa-KINc for the inhibitor did not reach the
sensitivity of wild-type PKBa. These results suggested a strong
correlation between the efﬁcacy of AKT inhibitor VIII and
the presence of the PKB PH domain-induced cavity.
In summary, the association of the PH domain residue Trp
80 to AKT inhibitor VIII through the PH domain-induced
cavity would block PKB in the inactive PH-in conformer,
preventing Thr 308 accessibility and it being phosphorylated.
A similar mechanism occurs in PKBc; however, the reduced
accessibility of Trp 79 decreases the efﬁciency of the
inhibitor. To our knowledge, this is the ﬁrst time the
presence of a PH domain-induced cavity in PKBa has been
demonstrated.
The loss of PKB conformation change upon inhibitor
binding was not a fully satisfactory explanation for the loss of
Ser 473 phosphorylation. Therefore, the position of the C-
terminal HM of PKB in its PH-in conformation relative to
AKT inhibitor VIII binding was investigated using molecular
modelling.
The only available crystal structure by Yang et al. (PDB
code: 1O6K) [16,22] demonstrated that a modiﬁed HM (in
which Ser 473 was mutated to an Asp) was positioned in a
hydrophobic grove in the N lobe of the isolated active PKBb
kinase domain; the positioning of the HM in inactive full-
length PKB has not been investigated. Figure 4A illustrates
the positioning the HM of PKBa on the PKBa kinase domain
in its PH-in conformer after a simulation of 11 ns, as depicted
by the crystal structure [16]. The dynamic model showed that
the HM passed right across the PH-induced cavity. Speciﬁ-
cally, the sequence F469XXF472S of HM was kinked above the
cavity, thus positioning Phe 469 at a binding distance (3.5 A ˚ )
from Trp 80.
Figure 3. The Lower Sensitivity of PKBc for AKT Inhibitor VIII Can Be Partially Reversed by Creating a Chimera (PHa-KINc)
(A) A dynamic model of the PH-in conformation of PKBc after 10-ns run is shown in panels (a) and (b) (cross section at the level of Trp 79). NIH3T3 cells
expressing GFP-PKBc or a mutant in which Trp 79 was changed to an Ala (W79A) were treated for 30 min with different concentrations of AKT inhibitor
VIII as indicated prior to 5-min PDGF stimulation. Thr 308 and Ser 473 phosphorylations were detected by western blot using phosphospecific
antibodies, and the quantifications were done using the Odyssey/LI-COR fluorescence detection system. The data are presented in percentage of Thr
308 (left graph) or Ser 473 (right graph) phosphorylations upon PDGF stimulation for each construct.
(B) Two dynamic runs of the PH-in conformation of the chimera PHa-KINc of 10 ns and 8 ns are presented in panels (a and b) and (c and d), respectively.
The dynamic models show that the replacement of PH and linker of PKBc by those of PKBa in the chimera PHa-KINc lead to a partial reopening of the
PH-induced cavity in the kinase domain KINc of the chimera. NIH3T3 cells expressing GFP-PKBc or GFP-CHIM PHa-KINc were treated for 30 min at
different concentrations of AKT inhibitor VIII as indicated prior to 5-min PDGF stimulation. Thr 308 and Ser 473 phosphorylations were detected by
western blot using phosphospecific antibodies and the quantifications were performed using the Odyssey/LI-COR fluorescence detection system. The
data are presented as a percentage of Thr 308 (left graph) or Ser 473 (right graph) phosphorylations upon PDGF stimulation for each construct. The p-
values were calculated using an unpaired t-test with Welch’s correction on a minimum of three independent experiments.
A single asterisk (*) and double asterisks (**) indicate p , 0.025 and p , 0.001, respectively. Error bars indicate the standard error of the mean.
doi:10.1371/journal.pbio.1000017.g003
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Regulation of PKB Inactive ConformerFrom this model, Gln 218 was identiﬁed as being at an
interacting distance for Ser 473. In addition, this residue
appeared to be at about 5 A ˚ from AKT inhibitor VIII in the
dynamic interaction model (Figure S1). Therefore, muta-
genesis was performed to assess its potential role in the HM
position and its relation to the inhibitor binding. By mutating
Gln 218 to Ala in GFP-PKBa, the basal as well as PDGF-
stimulated Ser 473 phosphorylation decreased signiﬁcantly,
suggesting that this newly identiﬁed residue was critical for
the stability of the Ser 473 phosphorylation (Figure 4B). This
effect was not due to an impaired translocation of GFP-PKBa
Q218A compared to GFP-PKBa wt upon PDGF stimulation
(Figure 4B, bottom panel). Indeed, the level of Thr 308
phosphorylation upon stimulation was not modiﬁed signiﬁ-
cantly (Figure 4B, top panel). The recovery of Ser 473
phosphorylation upon pretreatment with okadaic acid prior
to PDGF stimulation indicated that the loss of Ser 473
phosphorylation in GFP-PKBa Q218A mutant was due to an
enhanced dephosphorylation (Figure 4C). A plausible ex-
planation for this result was that the HM might be incorrectly
positioned and thus was becoming more accessible to
phosphatases.
In order to determine whether the Gln 218 Ala mutation
affected the binding of AKT inhibitor VIII, the effect of an
optimal (5 lM) and suboptimal (1 lM) dose of inhibitor VIII
on Thr 308 phosphorylation was tested (Figure 4D). The
enhanced inhibition of Thr 308 phosphorylation in the Gln
218 Ala mutant at 1 lM inhibitor suggested that the HM and
the inhibitor might compete for the same or a proximate
binding site.
In summary, the position of the HM in the inactive and
activated state of PKB is likely to be very similar. The
interaction between the Phe 469 and the Trp 80 suggested
that a role of the HM motif in the regulation of PKB prior to
its translocation and Ser 473 phosphorylation could be
envisioned. Furthermore, the C-terminal HM and AKT
inhibitor VIII could overlap at a common binding site.
To determine whether the HM was implicated in AKT
inhibitor binding as well as competing for the same (or a
close) binding site, a deletion mutant of the last 39 residues of
PKBa C-terminal part was made (Figure 5A). A dose-
dependent inhibition of Thr 308 phosphorylation by AKT
inhibitor VIII was performed on wild-type PKBa and mutant
PKBaD Ct. The deletion of the PKBa C-terminal part did not
prevent the inhibition of Thr 308 phosphorylation by AKT
inhibitor VIII. Moreover, a low dose of inhibitor (1 lM)
slightly, but signiﬁcantly, lowered Thr 308 phosphorylation in
PKBaD Ct compared to wild-type PKBa. This result showed
that the binding of the inhibitor was not dependent on the C-
terminal part of PKB and indicated further that the C-
terminal HM and AKT inhibitor VIII could potentially be
competing for a common or close binding site on the kinase
domain.
To understand the mechanism involved in the loss of Ser
473 phosphorylation upon AKT inhibitor binding, experi-
ments with okadaic acid and the inhibitor were performed
(Figure 5B). Since the data in Figures 4D and 5A suggested
that the HM and AKT inhibitor VIII could compete for the
same binding site, the inhibitor binding could lead to an
incorrect positioning of the HM, leading to an increased S473
dephosphorylation. A similar mechanism was shown above
when mutating the residue Gln2 1 8 .A l t e r n a t i v e l y ,t h e
inhibitor binding could prevent the phosphorylation of Ser
473 by steric hindrance. As previously described [14], the
inhibition of PP2A family of phosphatases by okadaic acid
induced the phosphorylation of Ser 473 (but not Thr 308) to a
similar extent as PDGF stimulation. However, the pretreat-
ment with inhibitor VIII prior to okadaic acid, with and
without PDGF, prevented the phosphorylation of Ser 473.
This result suggested that loss of Ser 473 phosphorylation was
likely to be due to the loss of accessibility of Ser 473 residue
to upstream kinase(s) rather than a dephosphorylation.
Conclusion
The novel ﬁndings from this study are summarised in
Figure 6 (see ﬁgure legend). The molecular mechanism of
interaction of the allosteric inhibitor AKT inhibitor VIII to a
critical PH domain residue, Trp 80, was consistent with the
model of binding through a PH-induced cavity formed in the
kinase domain of PKB. This cavity was present in PKBa,
whereas it was negligible in PKBc. Chimera constructs of the
PH and kinase domains suggested that the dimensions of the
cavity were strongly correlated with the sensitivity to the
inhibitor.
Figure 4. The Position of the C-Terminal Hydrophobic Motif (HM) of PKBa in the PH-in Conformer Is at Close Proximity to its Position after Stimulation
and Interferes with AKT Inhibitor VIII Binding
(A) PKBa C-terminal hydrophobic motif (HMa) (orange) interacting with PKBa kinase domain (green) in the PH-in conformer is presented in the model
panels (a) and (b) (cross section). The PH domain is in pink, and the PH domain residue Trp 80 is in red. The model shows that two phenylalanines (in
yellow) from the sequence F469XXF472S of HM are found positioned right above the PH-induced cavity in PKBa kinase domain. The Phe 469 is at binding
distance (;3.5 A ˚) from Trp 80 (panel [b]). The principal amino acid residues are indicated.
(B) NIH3T3 cells expressing GFP-PKBa wt or a mutant Q218A, were treated for 30 min with 5 lM AKT inhibitor VIII prior to 5-min PDGF stimulation as
indicated. Thr 308 and Ser 473 phosphorylations of exogenous and endogenous PKB were detected by western blot using phosphospecific antibodies.
Total protein was detected using a pan AKT antibody. The histogram presents the quantification of Ser 473 phosphorylation as a percentage of maximal
phosphorylation upon PDGF stimulation in GFP-PKBa wt. A one-sample t-test was performed (triple asterisks [***]) showing an extremely significant
difference with p , 0.0001. An unpaired t-test with Welch’s correction (single asterisk [*]) shows a very significant difference with a p , 0.05. The
bottom panels show confocal images at mid-section of NIH3T3 cells expressing GFP-PKBa wt or GFP-PKBa Q218A prior to (No Stim) or upon 5-min
PDGF stimulation. endo, endogenous; OKA, okadaic acid.
(C) NIH3T3 cells expressing GFP-PKBa wt or the mutant (Q218A), were treated for 45 min with 1 lM of okadaic acid prior to 5-min PDGF stimulation as
indicated. In the top panels, Ser 473 and Thr 308 phosphorylations were detected by western blot using phosphospecific antibodies. Total protein was
detected using a pan AKT antibody. The histogram presents the quantitative analysis of Ser 473 phosphorylation as a percentage of PDGF stimulation in
GFP-PKBa wt, from three independent experiments.
(D) NIH3T3 cells expressing GFP-PKBa wt or mutant Q218A were treated for 30 min with different doses of AKT inhibitor VIII (AKT inh VIII) prior to 5-min
PDGF stimulation as indicated. Thr 308 phosphorylation was detected by western blot using a phosphospecific antibody. Total protein was detected
using a pan AKT antibody. The histogram presents the quantitative analysis of Thr 308 phosphorylation as a percentage of PDGF stimulation in wild
type, from eight independent experiments. An unpaired t-test with Welch’s correction was performed with (double asterisks [**]) representing p ,
0.005.
doi:10.1371/journal.pbio.1000017.g004
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Regulation of PKB Inactive ConformerThe in vivo FRET data showed that in the presence of AKT
inhibitor VIII, PKB was maintained in its PH-in conforma-
tion. In this conformation, Thr 308 and Ser 473 phosphor-
ylation were impaired. However, a difference in the
inhibition of phosphorylation between the two sites was
observed. The inhibition of phosphorylation on Thr 308 was
linked to PKB being maintained in its PH-in conformation
and not being accessible to PDK1.
Recently published in vitro data indicated that the binding
of PKB PH domain to phosphoinositides did not seem to be
affected by the inhibitor interaction [21]. However, the
translocation of the GFP-PKB-mRFP reporter was prevented
in presence of inhibitor. These results indicated that the
maintenance of PKB at the plasma membrane appeared to
require a change in conformation of the protein. The lack of
PKB translocation could explain the loss of Ser 473
phosphorylation upon inhibitor binding. However, our
results indicated that the inhibitor binding created a steric
hindrance preventing the upstream kinase(s) from phosphor-
ylating Ser 473.
We have addressed the possible molecular mechanisms
involved in the regulation of the PKB inactive conformation
by examining intramolecular domain interaction dynamics.
The discovery of a PH-kinase domain interface in relation to
Figure 5. The Loss of Ser 473 Phosphorylation in PKBa upon AKT Inhibitor VIII Binding Is Due to Steric Hindrance
(A) NIH3T3 cells expressing GFP-PKBa;pha; wt or GFP-PKBaD Ct, deleted from the C-terminal HM motif (last 39 amino acids), were treated for 30 min
with different concentrations of AKT inhibitor VIII prior to 5-min PDGF stimulation (stim) as indicated. Thr 308 and Ser 473 (only for wild type)
phosphorylations were detected by western blot using phosphospecific antibodies, and the quantifications were performed using the Odyssey/LI-COR
fluorescence system. For statistical analysis, a two-tailed paired t-test was done from six independent experiments. Double asterisks (**) indicate p-
values , 0.001 at a concentration of 1 lM AKT inhibitor VIII.
(B) NIH3T3 cells expressing wild-type GFP-PKBa were treated for 30 min with 5 lM of AKT inhibitor VIII (VIII) followed by 1 lM of okadaic acid (OKA) for a
further 40 min prior to 5-min PDGF stimulation as indicated. Ser 473 (left panels) and Thr 308 (right panels) phosphorylations were detected by western
blot using phosphospecific antibodies, and the quantifications were done using the Odyssey/LI-COR fluorescence system. The data are presented as a
percentage of PDGF stimulation.
Error bars indicate the standard error of the mean.
doi:10.1371/journal.pbio.1000017.g005
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role of PKB quaternary structure in the control of this critical
regulator. Yet, the role played by the ﬂexible linker that joins
the PH and the kinase domains close to this interface, might
also be important to comprehend fully this regulation.
In addition, we have depicted the possible molecular
mechanism involved in the association of a new class of
selective allosteric inhibitors that to date had remained
elusive. We anticipate this will facilitate the optimisation of a
new generation of more potent or more selective inhibitors.
Materials and Methods
Materials and antibodies. Okadaic acid sodium salt and AKT
inhibitor VIII were from Calbiochem (Merck KGaA). Human PDGF
was from R&D Systems. Phospho-Akt Thr-308 (both rabbit polyclonal
and monoclonal) and Ser-473, as well as pan Akt, were from Cell
Signaling (New England BioLabs UK). Anti-GFP antibodies were in-
house monoclonals. Other chemicals were from Sigma-Aldrich. Glass-
bottom microwell culture dishes (35 mm; MatTek dishes) were from
MatTek Corporation. The Odyssey blocking buffer was from LI-COR
UK. The IRdye 800 anti-rabbit and IRdye 700 anti-mouse were used as
secondary antibodies for the LI-COR/Odyssey system (from Rockland
Incorporated).
Fusion constructs design and direct site mutagenesis. pEGFP-HA-
Akt construct was described previously (murine AKT1; Genbank
accession number NM_009652) [23]; to simplify, we called this
construct GFP-PKBa.
GFP-PKB-mRFPwascreatedbyputtingPCR-ampliﬁedmRFP(EcoRI-
XbaI)insteadofyellowﬂuorescentprotein(YFP)inthevectorpCDNA3-
GFP-PKB-YFP (described previously [14,24]), using the oligonucleotides
mRFP-Ct sense: AGAGAATTCGCCTCCTCCGAGGA CGTCATCAAG-
GAGTTCATGCGCTTCAAGG and mRFP-Ct antisense: ATCTCTAGA
TTATGCACCGGTGGAGTGGCGGCCCTCGGCGCGCTCG
TACTGTTCC.
Note that an extra XbaI site had to be removed using the Quick
Change mutagenesis kit from Stratagene in the pCDNA3-GFP-PKB-
YFP construct before the subcloning of mRFP (EcoRI-XbaI). The
W80A mutation on GFP-PKB-mRFP was performed by Maria Deak
from Dario Alessi’s laboratory (Dundee, UK).
GFP-PKBaD Ct was created by PCR ampliﬁcation of GFP-PKBa
without the C-terminal part, using the oligonucleotides AKT1 DCt-
sense: GGCATGGACGAGCT GTACAAGGGT and AKT1 DCt anti-
sense: TACGGATCCTCACTCCTCATCGAAATACCTGG.
The PCR ampliﬁcation was then placed instead of wild-type PKBa
in pEGFP-HA-Akt (GFP-PKBa) construct using SalI-BamHI restric-
tion sites.
Figure 6. Mechanism of Inhibition of PKB Activity by AKT Inhibitor VIII
(A) The upper panel shows PKBa in its inactive conformation (PH-in) prior to stimulation. The interaction of the PH domain (light grey) and the kinase
domain (light blue) creates a PH domain-induced cavity in the kinase domain. The PH domain residue Trp 80 (red oval) interacts with the Phe 469 of C-
terminal HM in orange through the PH-induced cavity. Both regulatory residues (Thr 308 and Ser 473) are unphosphorylated. Upon PDGF stimulation
(lower panel), PKBa adopts its active (PH-out) conformation. PH and kinase domains separate, allowing the phosphorylation of the regulatory residues
Thr 308 of the T-loop of the kinase domain and Ser 473 (black discs) on the HM. The PH domain-induced cavity closes up, and the HM residues Phe 469,
Phe 473, and phosphorylated Ser 473 interact with the hydrophobic pocket.
(B) The upper panel shows the binding of AKT inhibitor VIII (dark blue) to the Trp 80 through the PH-induced cavity of PKBa in its inactive conformation.
The inhibitor and the C-terminal HM compete for binding of the same region. The dotted orange line shows the position of the C-terminal HM without
inhibitor. The position of the C-terminal HM in presence of the inhibitor is represented as a solid orange line. The orange arrow represents the
movement of the C-terminal. The lower panel depicts the locking of PKBa in the PH-in conformation. The binding of AKT inhibitor VIII prevents the
change in conformation upon PDGF stimulation and Thr 308 from being phosphorylated. The phosphorylation of Ser 473 is prevented by a steric
hindrance due to the binding of AKT inhibitor VIII in the same region as HM.
(C) The mutation of the PH domain residue 80 to alanine (white oval) creates a PKBa insensitive to the inhibitor. Despite the preincubation with AKT
inhibitor VIII, the drug fails to inhibit PDGF-induced change in conformation and activation of PKBa.
(D) PKBa kinase domain residue Gln 218, positioned at close proximity to the C-terminal HM, was mutated to Ala (black spot). The mutation of this
residue destabilises the positioning of the C-terminal HM, allowing Ser 473 to become more accessible to phosphatases. Upon PDGF stimulation, PKBa
Q218A translocation to the plasma membrane and change in conformation allow the phosphorylation of Thr 308. However, Ser 473 remains
dephosphorylated.
doi:10.1371/journal.pbio.1000017.g006
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pCDNA3-Myr HA AKT3 human (Addgene plasmid 9017). The
oligonucleotides used for the ampliﬁcation were PCR-PKBc sense:
GTCGACATGTACCCATACGATGTTCCAGATTACGCTTCCA-
GAATGAGCGATGTTACCATTGTGAAAGAAGGTTGG and PCR-
PKBc antisense: GGATCCTTATTCTCGTCCACTTGCAGA GTAG-
GAAAATTGAGGG. Prior to the PCR ampliﬁcation of PKBc,a n
internal BamHI site was removed in pCDNA3-Myr HA AKT3 by
direct site mutagenesis using: PKBc-BamHI-less sense:
CTTTCAGGGCTCTTGATAAAGGACCCAAATAAACGCCTTGG
and PKBc-BamHI-less antisense: CCAAGGCGTTTATTTGGGTCC
TTTATCAAGAGCCCTGAAAG. The PCR product was subcloned
into the intermediate cloning vector zero blunt TOPO from
Invitrogen, then excised using SalI-BamHI restriction enzymes. The
excised PCR ampliﬁcation was then put in phase in C-terminus of
GFP (instead of PKBa in the vector GFP-PKBa cut with SalI-BamHI.
The chimera of the PH domain and linker of PKBa in fusion with
the kinase domain and C-terminal of PKBc (GFP-CHIM PHa-KINc)
was done ﬁrst by creating a modiﬁed GFP-PKBa construct containing
a BamHI site using the oligonucleotides AKT1-BamON-sense:
GGGGCTGAAGAGATGGAGGGATCCCTGGCCAAGCCCAAGCAC
and AKT1-BamON-antisense: GTGCTTGGGCTTGGCCAGGGAT
CCCTCCATCTCTTCAGCCCC.
A PCR ampliﬁcation of PKBc kinase domain was then performed
using the oligonucleotides ChimAKT3-sense: AGTGGATCCCTGGC-
CAAGCCCAAGCACAGAAAGA CAATGAATGATTTTGACTATTTG
and ChimAKT3-antisense: ACTGGATCCTTA TTCTCGTCCACTTG-
CAGAGTAGG
The PCR product was cut with BamHI and inserted in the modiﬁed
GFP-PKBa vector containing a BamHI site.
The mutants of PKB were obtained by direct site mutagenesis using
the Quick Change mutagenesis kit from Stratagene using the
oligonucleotides PKBa-W80A sense: CATCCGCTGCCTGCAGGCGAC-
CACAGTCATTGAGCGC; PKBa-W80A antisense: GCGCTCAAT-
GACTGTGGTCGCCTGCAGGCAGCGGATG; PKBa-Q218A sense:
CGGCCCTCAAGTACTCATTCGCGACCCACGACCGCCTCTGC;
PKBa-Q218A antisense: GCAGAGGCGGTCGTGGGTCGCGAATGAG-
TACTTGAGGGCCG;PKBc-W79A sense: CAGATGTCTCCAGGCGAC-
TACTGTTATAGAGAGAACATTTCATG; and PKBc-W79A-antisense:
CATGAAATGTTCTCTCTATAACAGTAGTCGCCTGGAGACATCTG.
Cell culture and transfections. NIH3T3 cells from ATCC were
maintained in DMEM 10% Donor Calf Serum (DCS) and seeded at
150,000 in a well of a six-well plate or in a MatTek dish. The
transfection was done with 2 lg of DNA of the different constructs
(2þ2 lg for cotransfections) using Lipofect AMINE/PLUS reagent
(GIBCO-BRL) in OPTIMEM medium (GIBCO-BRL) as recommended
by the manufacturer. The cells were left for 3 h in the transfection
mix, and then the medium was removed and replaced with DMEM
10% DCS. The experiments were performed 24 or 48 h after
transfection.
Lysis conditions. After stimulation or treatment as indicated, the
cells were lysed for 15 min on ice in lysis buffer (20 mM Tris-HCl [pH
7.4], 150 mM NaCl, 100 mM NaF, 10 mM Na4P2O7, 10 mM EDTA
supplemented with COMPLETE protease inhibitor cocktail tablet
[Roche]). To terminate the reaction, 43 SDS sample buffer (125 mM
Tris-HCl [pH 6.8], 6% SDS, 20% glycerol, 0.02% bromophenol blue
supplemented with 10% b-mercaptoethanol) was added, and the
samples boiled for 5 min. The proteins were separated on a 10% SDS-
PAGE gel.
Western blot analysis (classical ECL). After electrophoresis, the
polyacrilamide gels were transferred onto PVDF membrane (Immo-
bilon P; Millipore) and incubated in blocking buffer TBS-T (10 mM
Tris-HCl [pH 7.4], 150 mM NaCl, 0.05% Tween-20) supplemented
with 3% BSA for 1 h. The membranes were then incubated with the
different antibodies: phospho-Akt (Thr-308) antibody (rabbit poly-
clonal from Cell Signaling), phospho-Akt (Ser-473) (rabbit polyclonal
antibody raised against the C-terminus phospho-peptide HFPQFpSY-
SASS of Akt1) or with the pan AKT at 1:1,000 for 1 to 3 h in TBS-T/
3% BSA. The membranes were then washed in TBS-T with 0.2%
Tween-20 and 1% milk for 1 h. The secondary HRP-antibodies were
used at 1:5,000 in TBS-T with 5% milk for 1 h. Western blots were
revealed by incubation with ECL (Amersham Biosciences). Density
analysis of bands was done with NIH ImageJ 1.33u (U.S. National
Institutes of Health, http://rsb.info.nih.gov/ij/). The analysis was
performed by subtracting the background of the autoradiography
and normalised as indicated on the graphs.
Western blot (LI-COR/Odyssey ﬂuorescence system). After electro-
phoresis, the polyacrilamide gels were transferred onto PVDF
membrane (Immobilon FL; Millipore), incubated in the Odyssey
blocking buffer for 1 h, and then with the different antibodies
phospho-Akt (Thr-308) antibody (rabbit polyclonal or monoclonal
from Cell Signaling) or phospho-Akt (Ser-473) (rabbit polyclonal
antibody raised against the C-terminus phospho-peptide HFPQFpSY-
SASS of Akt1) at 1:1,000 together with an anti-GFP in-house
monoclonal at 1:2,500 for 4 h in Odyssey blocking buffer. The
membranes were then washed in PBS 0.2% Tween-20 with 1%
odyssey buffer for 1 h. The secondary antibodies IRdye 800 anti-
rabbit and IRdye 700 anti-mouse (Rockland) were used at 1:2,500 and
1:5,000, respectively, in Odyssey blocking for 1 h. The blots were
scanned with the infrared LI-COR scanner, allowing for simultaneous
detection of two targets (anti-phospho and total protein) in the same
experiment. For each experiment, the values of the phospho bands
were normalized for the total amount of protein in each lane.
Fo ¨rster resonance energy transfer (FRET) by two-photon ﬂuores-
cence lifetime imaging microscopy (FLIM). NIH3T3 cells were seeded
at 150,000 on 35-mm glass-bottom tissue culture dishes (MatTek) and
transfected as described above. Twenty-four hours after transfection,
the cells were treated in DMEM containing 10% DCS. The cells were
washedtwicewithPBS,andthenﬁxedin4%paraformaldehydeinPBS
for 10 min. The dishes were washed twice with PBS, and then 2 ml of
PBS supplemented with 2.5% (w/v) DABCO as an antifade was added
to the dishes. The images were acquired straightaway or stored at 4 8C.
Details about the method to detect FRET by time domain FLIM
was as previously described [14,25]. We used a nonparametric Mann-
Whitney test to compare the medians of the two datasets for the two-
photon FLIM data using GraphPad InStat software (version 3.0 for
Mac-2001). To interpret the distribution of data, box and whisker
plots were used. The box and whisker plot is a histogram-like method
for displaying upper and lower quartiles, and maximum and
minimum values in addition to median.
Molecular modelling. In order to check the validity of the models,
we performed several molecular dynamics simulations. Vacuum
calculations were performed on an SGI Octane workstation using
InsightII and Discover ver. 2000 (Accelrys). The hydrated models
calculations were performed using NAMD [26] software v2.6 and
CHARMM 27 force-ﬁeld. All simulations were performed on a 32-
processor IBM PC-cluster using 8 to 16 processors. The simulation
boxes were built using VMD v1.8.6 facilities. All images were captured
from VMD [27] using the internal ray-tracing software Tachyon.
Two models were built starting from the model of the PH/KIN
PKBa complex previously described [14]. The whole complex was
immersed in a box of water, fully ionized, with all charges neutralized
by counter ions, and salt was added to reach the biological
concentration of 150 mM. The wild type was built ﬁrst, and the
W80 was subsequently mutated into A80.
Model 1 (wild type) totalled 47,114 atoms with 13,394 water
molecules (TIP3P) in a box of 88.94 3 73.99 3 77.87 A ˚ 3,a tT ¼ 300 K
and P ¼ 1 bar. Time of simulation: 6.22 ns.
Model 2 (W80A) totalled 47,103 atoms with 13,395 water molecules
(TIP3P) in a box of 88.94 3 73.99 3 77.87 A ˚ 3,a tT ¼ 300 K and P ¼ 1
bar. Time of simulation: 6.13 ns.
During the two simulations, a water cavity opened quickly (after
about 0.2 ns) just in front of residue 80 going from the outer surface
of the protein directly to the surface of residue 80.
For wild-type (PKBa W80), the cavity was stable and almost as wide
as deep. W80 was located about 8–8.5 A ˚ from the outer surface of the
protein, and the cavity had a maximum opening of around 8–9 A ˚ . The
cavity was full of water (see Figure 2).
For the W80A mutant, the cavity appeared more unstable with
ﬂuctuations and was deeper than it was wide. A80 was located 14–15
A ˚ from the protein surface (compared to 8–8.5 A ˚ in the wild type),
and the maximum opening was around 6–7 A ˚ . The cavity was again
full of water.
Positioning of the C-terminal. The ﬁnal model of the wild-type PH/
KIN PKBa complex after molecular dynamics simulation was super-
imposed (kinase domain only) over the published X-ray structure of
AKT-2 (PKBb) [22] (PDB codes: 1O6K and 1O6L). After super-
imposition, the kinase domain of PKBb was deleted, leaving the C-
terminal (466–479) of PKBb lying on the surface of the PH/KIN
complex of PKBa. The C-terminal was then mutated to correspond to
the sequence of the C-terminal of PKBa, as below:
1O6K:QRTHFPQFDYSASI
PKBa:RRPHFPQFSYSASG
Underlined residues were mutated during the building (only three
residues). The bold and underlined S474D mutation, which was
introduced in PKBb [16], was also present (as S473D) in the ﬁrst
model of PKBa. However, in a second step, the reverse mutation
D473S was built in order to get back to the wild-type model.
With the D473 mutation, a ﬁrst model was built in a box of
dimensions: 78.74391.28373.66 A ˚ 3,a tT¼300 K and P¼1 bar, with
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simulation time: 3.43 ns. During the simulation, an interaction
between R465 and D473 was observed due to the fact that the C-
terminal was truncated on its N-terminus. Thus the N-terminal of the
C-terminal was moved toward the surface of the protein away from
D473, and a second model was built: 79.52 3 91.79 3 73.82 A ˚ 3,a tT ¼
300 K and P ¼ 1 bar, with a total amount of 49,619 atoms of which
14,153 water molecules, simulation time: 7.2 ns.
With the reverse D473S mutation, one model was built: 78.74 3
91.28 3 73.66 A ˚ 3,a tT ¼ 300 K and P ¼ 1 bar, with a total amount of
48,531 atoms of which 13,872 were water molecules, simulation time:
11.2 ns.
Even though the C-terminal is an isolated short peptide strand, it
displays a sustainable stability for the duration of the various
molecular dynamics runs. This is due to many close contacts and
hydrogen bonds with mainly the kinase domain. There are hydrogen
bondings of the C-terminal backbone with several polar groups of the
kinase domain: F472 with S216, F469 with Q218, P467 with T219, and
a strong salt bridge between R465 and E184. A full p-stacking (face to
face) between the F462 and F225 residue is observed. Very close
contacts between the C-terminal and the following residues in the
kinase domain: K183, V187, A188, H220, D221, and L223 are also
observed. It is of note that when the C-terminal was added to the PH/
KIN complex, the number of salt bridges between the PH and kinase
domains increased from seven bridges for the PH/KIN complex to ten
bridges for the full PH/KIN/C-term complex. This implied a
stabilization of the AKT complex upon binding of the C-terminal.
AKT inhibitor VIII binding simulation. The starting point was the
previously equilibrated model ofthePH/KINcomplexof humanPKBa
with the cavity ﬁlled with water molecules. The inhibitor was carefully
docked within the water cavity. The complex was submitted to a
simulated annealing procedure to get the best docking solution using
the Afﬁnity module within Insight software. Initially, random docking
was performed with a ﬂexible ligand without electrostatic interactions
and with Van der Waals interactions reduced to 10%. At a second
stage, the best solutions were submitted to a simulated annealing (SA)
procedure with all nonbonded interactions on all free protein side-
chains and the tethered backbone. Fifty stages of SA of 100 fs each
were performed from 500 to 300 K before full minimization (1,000
steps). The best solution was submitted to several 1-ns molecular
dynamics without any constraints. In all cases, the benzimidazolone
moiety located at the extremity of the inhibitor was associated by
hydrogen bonding to the residues Q218, T219, or S216. The
imidazolo-quinoxaline moiety remained in close contact with the
key residue W80 (Figure S2). The aromatic part of the inhibitor, which
was embedded inside the cavity, was surrounded by a hydrophobic
core containing: I186, F225, and H194 residues, as well as the W80.
Supporting Information
Figure S1. Molecular Dynamic Simulation of AKT Inhibitor VIII in
PKBa PH-in
The dynamic structure of the PKBa PH domain (pink) and the
reconstructed kinase domain (green) is shown in complex (PKBa PH-
in conformer). The secondary structure of the kinase domain is
represented as a white ribbon. The PH domain residue Trp 80 is
shown in red. The position of AKT inhibitor VIII (blue) is presented
following a dynamic run of 1 ns. The inhibitor is deeply and stably
embedded in the cavity of wild-type PKBa PH-in conformation. A
distance of 4 A ˚ (between the two N) or less than 3 A ˚ (between H and
N) can be measured from the quinoxalin head of AKT inhibitor VIII
to the Trp 80, suggesting a possible interaction by hydrogen bonding.
The kinase domain residue Q218 highlighted in yellow is positioned
at less than 5 A ˚ from AKT inhibitor VIII.
Found at doi:10.1371/journal.pbio.1000017.sg001 (2.15 MB PDF).
Figure S2. Distance between the Nitrogen Atom of the Imidazolo-
Quinoxaline Moiety of Inhibitor VIII and the Nitrogen of the Indole
Nucleus of Trp 80 upon Time
Found at doi:10.1371/journal.pbio.1000017.sg002 (411 KB PDF).
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